FDA Accepts Supplement Application for GLEEVEC (Imatinib Mesylate)
The FDA has accepted a supplemental application for GLEEVEC, indicating ongoing regulatory activity.
Asset / Drug
Drug and asset intelligence for GLEEVEC with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Tyrosine Kinase Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.